Why Airbnb, SMCI, and Wynn Resorts Soared
Last Friday, Airbnb (ABNB) nearly took out its 52-week high when the stock gained 14.45%. Billionaire Airbnb co-founder Joe Gebba will join Elon Musk’s Department of Government Efficiency (‘DOGE’).Stock markets are anticipating that the role will help ABNB stock’s prospects. Similarly, investors expect Musk’s Tesla (TSLA) will benefit in the long-term from Musk leading DOGE.On Feb. 13, 2025, Airbnb posted a Q4 GAAP earnings per share of $0.73. Revenue increased by 11.7% Y/Y to $2.48 billion. It is investing up to $250 million to launch and scale its new businesses. EBITDA margin will top at least 34.5%.Super Micro Computer (SMCI) gained 32.1% last week. After posting preliminary Q2 results, the firm announced a $700 million private placement. The convertible senior notes mature in 2028 and pay 2.25%. SMCI said that it would file its financial results by Feb. 25. Failing to do so would result in a delisting within 10 days.Wynn Resorts (WYNN) gained 10.38% last Friday to close at $88.82. The firm reported flat revenue growth of $1.84 billion. Despite the modest results, WYNN stock rallied as shareholders bet management was too conservative with its outlook. Events like the Super Bowl will lift the current quarter revenues.Macau is a tailwind for Wynn. Furthermore, the Chinese New Year likely boosted revenue.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


